Yea I thought of that but at this SUB 1B Enter. Value, should Covid program (regardless of results) have such a decimating impact on the valuation?
I had thought given the royalty stream and cash level, of all bio land, ENTA would hold up better than others, but it actually has been worse or at least as bad as other small/med bios
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.